Drugs / Lunasin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02709330 | Apr 2016 → Sep 2017 | amyotrophic lateral sclerosis | Richard Bedlack, M.D., Ph.D. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lunasin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02709330 ↗ |
| Modality | Peptide | “Lunasin, a soy peptide that reportedly alters histone acetylation in vitro” PMID 30663902 ↗ Jan 2019 |